Luspatercept-AAMT Drug Asset Due Diligence Report 2026

This Luspatercept-AAMT Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

132

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Luspatercept-AAMT can convert its Fc fusion protein profile and ACVR2B x GDF11 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Luspatercept-AAMT (query alias: luspatercept)
Modality / target	Fc fusion protein; ACVR2B x GDF11; ACVR2B inhibitors, GDF11 inhibitors
Highest global status	Approved
Originator	Acceleron Pharma, Inc.
Active developers	Celgene Corp., Acceleron Pharma, Inc., Bristol Myers Squibb Co.

The MCP disease footprint includes Non-transfusion dependent thalassaemia, Anemia, Anemia, Sideroblastic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07636486	Phase 2/3	Not yet recruiting	90	Erythroid response
NCT07663864	Phase 1/2	Recruiting	40	Time of 50% increase in hemoglobin levels from baseline
NCT07681440	Not Applicable	Terminated	30	Participant age

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Updated overall survival (OS) and long-term transfusion-independence (TI) from the phase 3 COMMANDS trial in erythropoiesis-stimulating agent (ESA)–naive patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).

Phase 3; n=363; evaluation: Positive. Reported fields: Hb(increase ≥1.5 g/dL) = 58.6 % ; Hb(increase ≥1.5 g/dL) = 80.2 %

Impact of prior exposure to erythropoiesis-stimulating agents (ESA) on thromboembolic events in patients with myelodysplastic syndromes receiving luspatercept: A real-world TriNetX-based study.

Not Applicable; n=1602; evaluation: Positive. Reported fields: Arterial thrombosis(1 year) = 7.2 % ; Arterial thrombosis(1 year) = 7.4 %

UPDATED OVERALL SURVIVAL AND LONG-TERM TRANSFUSION INDEPENDENCE IN ESA-NAIVE PATIENTS WITH LOWER-RISK MDS: RESULTS FROM THE PHASE 3 COMMANDS TRIAL

Phase 3; n=203; evaluation: Positive. Reported fields: death = 43.0 % ; death = 36.3 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Luspatercept-AAMT addresses Non-transfusion dependent thalassaemia, Anemia, Anemia, Sideroblastic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fc fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2008-02-20	Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO